Scalable ADC Development Built for CMC Success
Xcellon Biologics advances your program from lead candidate to IND-ready material with our ADC & Bioconjugate Development services. Using emerging conjugation techniques such as our enzymatic glycoengineering (EG) platform for site-specific conjugation we can deliver high quality materials to support your projects.
Supporting emerging technologies we employ a full range of transitional chemistries such as cysteine, lysine, and click chemistries. From this repertoire we can design conjugates that are both scientifically optimized and manufacturable at scale. Coupled with our platform downstream purification (DSP) process tailored for ADCs manufacturing, we deliver reproducible, high-quality material for toxicology, preclinical, and IND-enabling studies.
Pain Points in ADC Development
Most ADC development bottlenecks occur during conjugation and purification. Traditional conjugation methods often result in heterogeneous products, variable DARs, and purification challenges. Xcellon reduces this risk by integrating site-specific conjugation with a proven ADC DSP platform, ensuring consistent quality and easier scale-up.
What We Offer
-
Developability Assessment
In-depth characterizations of conjugates such as DAR profiling, biophysical evaluations, serum stability assessments and peptide mapping . -
Conjugation optimization
DoE-guided evaluation of conditions, DAR control, and linker-payload combinations. -
Site-specific conjugation via EG platform
With options for cysteine, lysine, and click chemistry. -
Platform DSP purification
Integrated process for payload clearance, aggregation reduction, and impurity removal. Fully integrated into typical antibody purification workflow. -
Toxicology & IND material generation
Medium-scale production for preclinical studies.
Each development project builds on data from ADC lead selection services, ensuring continuity from discovery through scale-up. Optimized workflows established at this stage feed directly into bioprocess development, where upstream and purification strategies are further refined for seamless GMP transfer.
Advance your ADC from lead to IND with confidence
Accelerate your ADC journey from lead candidate to IND with precision and speed. Leverage expert guidance to de-risk development and unlock clinical success.
FAQs For ADC & Bioconjugate Development
We combine the precision of our site-specific glycoengineering platform with the flexibility to apply other conjugation chemistries, all integrated into a platform DSP process proven to deliver homogeneous, scalable ADCs.
Yes, we generate medium-scale conjugates suitable for toxicology, pharmacology, and IND submissions.
Our glycoengineering platform remodels the Fc glycan to create uniform conjugation sites, enabling precise DAR control (2, 4, 6, or 8) with minimal aggregation. This consistency reduces variability across batches and lowers regulatory risk.
